Login to Your Account

FDA Letter Says Alkermes, J&J's Risperdal Consta Not Approvable

By Kim Coghill

Tuesday, July 2, 2002
Alkermes Inc.'s stock plunged 67.8 percent Monday after its partner, Janssen Pharmaceutica Products LP, said the FDA issued a non-approvable letter for Risperdal Consta, a twice-monthly injectable form of the anti-psychotic drug Risperdal. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription